Cargando…

An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C

Background: Hepatitis C virus (HCV) infection is one of the major causes of liver cirrhosis and hepatocellular carcinoma globally. The advent of direct-acting antivirals (DAAs) with high cure rates provides an opportunity to reduce the rising HCV disease burden. However, few studies have explored th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Pin-Sheng, Chang, Te-Sheng, Lu, Sheng-Nan, Su, Hsiang-Jou, Chang, Shu-Zhi, Hsu, Chia-Wen, Chen, Mei-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950306/ https://www.ncbi.nlm.nih.gov/pubmed/31817863 http://dx.doi.org/10.3390/ijerph16244981

Ejemplares similares

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
por: Chen, Chun-Hsien, et al.
Publicado: (2023)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
por: Tang, Kuo-Tung, et al.
Publicado: (2022)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
por: Chen, Yen-Chun, et al.
Publicado: (2022)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
por: Chang, Li-Jen, et al.
Publicado: (2022)

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
por: Hsieh, Yung-Yu, et al.
Publicado: (2023)

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Nonpolar Side Chains Affect the Photochemical Redox Reactions of Copper(II)–Amino Acid Complexes in Aqueous Solutions
por: Lin, Chen-Jui, et al.
Publicado: (2021)

Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals
por: Hsu, Cheng-Er, et al.
Publicado: (2022)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Natural Melanogenesis Inhibitors Acting Through the Down-Regulation of Tyrosinase Activity
por: Chang, Te-Sheng
Publicado: (2012)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol
por: Wang, Yi-Kai, et al.
Publicado: (2022)

Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients
por: Liu, Yen-Chun, et al.
Publicado: (2020)

Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
por: Chiu, Shao-Ming, et al.
Publicado: (2020)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
por: Hsu, Jui-Ting, et al.
Publicado: (2022)

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
por: Perez, Shira, et al.
Publicado: (2019)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study
por: Chang, Ming-Ling, et al.
Publicado: (2022)

Melanogenesis Inhibitory Activity of Two Generic Drugs: Cinnarizine and Trazodone in Mouse B16 Melanoma Cells
por: Chang, Te-Sheng, et al.
Publicado: (2011)

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
por: Sundberg, Isak, et al.
Publicado: (2018)

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data
por: Yen, Yi-Hao, et al.
Publicado: (2019)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients
por: Cheng, Chun-Han, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h970eieij3v63ms1q0u2tnprd6